Program
Cetuximab
Also written as “cetuximab”, “RPH-002” and “Cetuximab + Irinotecan”.
Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck · Head and Neck Neoplasms · Neoplasms, led by 26 companies.
Drug pageCetuximab: every studyMany companies study it; this page follows only the 90 they lead. All 565 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 300 open or running | phase 3since Jun 4, 2003 | Apr 30, 2002 | none ahead |
| Merck KGaA, Darmstadt, Germanyits history only | 170 open or running | phase 3since Sep 7, 2005 | Jul 28, 2005 | none ahead |
| Pfizerits history only | 53 open or running | phase 3since Oct 5, 2020 | Dec 1, 2010 | Dec 31, 2029phase 2 · NCT05226871 |
| Bristol-Myers Squibbits history only | 40 open or running | phase 3since Nov 17, 2017 | Jan 7, 2008 | none ahead |
| Hoffmann-La Rocheits history only | 41 open or running | phase 2since Dec 18, 2007 | Jul 3, 2007 | Aug 31, 2030phase 1 · NCT04929223 |
| R-Pharmits history only | 40 open or running | phase 3since Feb 20, 2026 | Sep 28, 2006 | none ahead |
| Sarah Cannon Research Instituteits history only | 41 open or running | phase 3since Nov 9, 2005 | Nov 2, 2005 | none ahead |
| Merckits history only | 22 open or running | phase 3since May 21, 2025 | May 21, 2025 | Mar 28, 2029phase 3 · NCT06997497 |
| Novartisits history only | 20 open or running | phase 2since May 16, 2012 | May 24, 2007 | none ahead |
| Pierre Fabreits history only | 20 open or running | phase 2since Sep 17, 2018 | Sep 17, 2018 | none ahead |
| Bayerits history only | 10 open or running | phase 1since Oct 28, 2013 | Oct 28, 2013 | none ahead |
| BOE Technology Groupits history only | 11 open or running | phase 2since Apr 10, 2026 | Apr 10, 2026 | Apr 2028phase 2 · NCT07551778 |
| Boehringer Ingelheimits history only | 10 open or running | phase 1since Dec 19, 2013 | Dec 19, 2013 | none ahead |
| Boneca | 10 open or running | phase 2since Jun 21, 2009 | Jun 21, 2009 | none ahead |
| Cinnagenits history only | 11 open or running | phase 3since Dec 31, 2017 | Dec 31, 2017 | none ahead |
| Daiichi Sankyoits history only | 10 open or running | phase 1since Jan 19, 2015 | Jan 19, 2015 | none ahead |
| Fosun Pharmaits history only | 11 open or running | phase 1since Apr 7, 2026 | Apr 7, 2026 | Jun 30, 2027phase 1 · NCT07543471 |
| GlaxoSmithKlineits history only | 10 open or running | phase 1since Oct 5, 2007 | Oct 5, 2007 | none ahead |
| Haisco Pharmaceutical Groupits history only | 11 open or running | phase 2since Aug 13, 2026 | Aug 13, 2026 | Sep 30, 2029phase 2 · NCT07790510 |
| Harrison Clinical Researchits history only | 10 open or running | phase 1since Jan 9, 2009 | Jan 9, 2009 | none ahead |
| Innate Pharmaits history only | 10 open or running | phase 2since Dec 17, 2015 | Dec 17, 2015 | none ahead |
| IntegraGenits history only | 10 open or running | phase 3since Nov 24, 2017 | Nov 24, 2017 | none ahead |
| Merrimack Pharmaceuticalsits history only | 10 open or running | phase 1since Oct 7, 2011 | Oct 7, 2011 | none ahead |
| Revolution Medicinesits history only | 11 open or running | phase 2since May 20, 2024 | May 20, 2024 | Sep 30, 2028phase 2 · NCT06445062 |
| Shanghai Celfuture Biotechits history only | 10 open or running | phase 2since Jan 4, 2023 | Jan 4, 2023 | none ahead |
| Verastemits history only | 11 open or running | phase 2since Jun 15, 2026 | Jun 15, 2026 | Jun 2027phase 2 · NCT07659795 |
Also a collaborator on its studies: Ono Pharmaceutical, AstraZeneca, Prologue Research International, Sanofi and Merck, S.L., Spain.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Boneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 21, 2009First study: phase 2 study in Head and Neck NeoplasmsFirst studyNCT00927147 · 17 enrolled · Finland
- Dec 9, 2018Named cetuximabINNProposed as its International Nonproprietary Name in WHO's List 120 · before, RPH-002
TargetBeta
“A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
The one study Boneca leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00927147Head and Neck Neoplasms · Finland | 2 | Terminated | Jun 2013 | 17 |
How it is read
Names in the registry
- “Cetuximab”, 57 entries
- “cetuximab”, 11 entries
- “RPH-002”, 2 entries
- “Cetuximab + Irinotecan”, 2 entries
- “Cetuximab + mFOLFOX6”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 34 studies
- Carcinoma, Non-Small-Cell Lung, 17 studies
- Squamous Cell Carcinoma of Head and Neck, 10 studies
- Head and Neck Neoplasms, 7 studies
- Neoplasms, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.